American Association for Cancer Research: Next-Generation PARP Inhibitor Demonstrates Clinical Benefit in Patients With Homologous Recombination Repair-Deficient Breast Cancer
April 09, 2024
April 09, 2024
SAN DIEGO, California, April 9 (TNSres) -- The American Association for Cancer Research issued the following news release:
* * *
DRUG HAS HIGHER SELECTIVITY FOR PARP1, IMPROVING SAFETY AND TOLERABILITY
* * *
Saruparib, a selective inhibitor of poly-ADP ribose polymerase 1 (PARP1), demonstrated a promising objective response rate and progression-free survival in patients with certain homologous recombination repair (HRR)-deficient breast cancers . . .
* * *
DRUG HAS HIGHER SELECTIVITY FOR PARP1, IMPROVING SAFETY AND TOLERABILITY
* * *
Saruparib, a selective inhibitor of poly-ADP ribose polymerase 1 (PARP1), demonstrated a promising objective response rate and progression-free survival in patients with certain homologous recombination repair (HRR)-deficient breast cancers . . .